PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study
Natalia Elliot | February 14, 2025 | News story | Clinical Research | Opthalmology, age-related macular degeneration, clinical trials
Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be used to fund a phase 1 study into its dry age-related macular degeneration (AMD) therapy, PST-611. The funding round was supported by existing investor Pureos BioVentures.
PST-611 is a non-viral vectorised therapy indicated for the treatment of dry AMD/geographic atropy (GA). It encodes the human transferrin protein – a crucial regulator of iron homeostatis – that has demonstrated the reduction of oxidative stress and inflammation while preserving the integrity of the retinal pigment epithelium in preclinical models. The phase 1 trial is set to start in Q2 of 2025 and aims to confirm the favourable safety profile of PST-611.
The funding will also support phase 2a trial preparation and implementation, and the development of PulseSight’s wider portfolio.
Judith Greciet, CEO of PulseSight Therapeutics said, “We are excited to have the funds to progress our lead programme, PST-611, which we believe holds the potential to become a major new treatment option for patients with dry AMD/GA. This financing enables us to execute on our goal of confirming the safety of our drug candidate and to then rapidly move into a phase 2 proof-of-concept study, to demonstrate transferrin’s ability to protect retinal cells and preserve vision.”
James Spargo
14/2/25
Related Content
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
